News
September 5, 2024
Abdera Therapeutics Announces FDA Orphan Drug Designation for ABD-147 for the Treatment of Neuroendocrine Carcinoma
Read
August 5, 2024
Fierce Biotech Names Abdera Therapeutics a “Fierce 15” Biotech Company of 2024
Read
June 27, 2024
Abdera Therapeutics Announces FDA Fast Track Designation for ABD-147, a Next-Generation Precision Radiopharmaceutical Therapy, for the Treatment of Patients with Extensive-stage Small Cell Lung Cancer
Read
May 23, 2024
Abdera Therapeutics Announces FDA Clearance of IND Application for ABD-147
Read
January 30, 2024
Abdera Therapeutics Expands Management Team and Board of Directors
Read
April 20, 2023
Abdera Therapeutics Debuts With $142 Million in Financing to Engineer and Advance Best-in-Class Antibody-Based Radiopharmaceuticals for Cancer
Read